In this issue:
Prostate biopsies for PI-RADS 5 and PSA density >15%
Adjuvant vs ESRT in men at high risk of recurrence
Mechanisms of enzalutamide resistance in mCRPC
Lesion volume + PSA density for diagnosis of clinically significant prostate cancer
Ipatasertib + abiraterone in mCRPC
18F-DCFPyL-PET/CT in biochemically recurrent prostate cancer
Predictors of all-cause and prostate cancer-specific mortality
177Lu-PSMA for mHSPC
Apalutamide for mHSPC
PSMA-targeted antibody-drug conjugate for mCRPC
Please login below to download this issue (PDF)